Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2002

View Archived Issues

Elan: 2001 review, 2002 projections

Pharmacological and clinical data on NXY-059 discussed in San Antonio

Selectin antagonist may have potential in the treatment of stroke according to rodent data

Addition of SM-20302 to tPA associated with beneficial outcome in thromboembolic stroke

Risk of thrombolysis-associated hemorrhage reduced by MMP inhibitor

CVS-3983: a promising lead inhibitor of the antitumor drug target matriptase

Antidepressant targeting GPCR enters human testing at Synaptic

Six-month follow-up results with OrCel treatment of venous ulcers

BSKB establishes Pyro Pharmaceuticals to handle new class of potential antibiotics

Long-term effects of CD154 blockade examined in experimental autoimmune encephalomyelitis

Bioenvision closes acquisition of Pathagon

Vion reports on progress in 2001

Texas Biotechnology 2001 report

BMS and Sanofi-Synthelabo withdraw irbesartan sNDA

Picovir NDA to be reviewed in March

Adolor conducts additional pivotal phase III trials of alvimopan in postoperative ileus

Pivotal trial of oral enoximone begins in advanced heart failure

Repligen and McLean Hospital collaborate on secretin studies in autism

Roche claims new compounds with utility in depression, etc.

Antitumor agents from Pfizer inhibit tyrosine kinases

Preparation and use of steroids for androgen- and estrogen-mediated diseases reported by Aventis

Scientists at Lilly synthesize inhibitors of multidrug resistance protein

PDE4 inhibitors in development at Sigma-Tau

Spanish lab designs selective muscarinic M3 receptor antagonists

Benzodiazepines with AMPA receptor-antagonist activity synthesized at Annovis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...